Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISIS 14803 Added to PegIFN/RBV in HCV Non-Responders
NCT00062816Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Jun 2003
- Primary completion
- Jan 2004
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
A Phase 2 trial of ISIS 14803 in hepatitis C (HCV), sponsored by Ionis Pharmaceuticals. Started Jun 2003; status: completed.
02
Drugs
ISIS 14803
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00062816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00062816.